文献速递心境障碍焦虑、强迫与应激相关障碍

PAC1受体拮抗剂PA-915在慢性应激小鼠模型中快速且持久的抗抑郁样效应

Rapid and long-lasting antidepressant-like effects of the pituitary adenylate cyclase-activating polypeptide receptor antagonist PA-915 in chronic stress mouse models.
PubMed 文献 · Mol Psychiatry · 2025-09-04

本研究在重复社交挫败应激、重复给予皮质酮和社会隔离饲养三种慢性应激抑郁小鼠模型中,评估小分子非肽高亲和力PAC1拮抗剂PA-915的行为效应。PA-915改善了应激小鼠强迫游泳试验中的不动时间增加,并在重复社交挫败应激小鼠中改善焦虑样和抑郁样行为及认知功能障碍。单次给药PA-915在蔗糖偏好试验中观察到持续8周的抗抑郁样效应,与氯胺酮相似;在非应激对照小鼠中未诱导过度活动、认知功能障碍或依赖等行为异常。

要点

  • PA-915在三种慢性应激小鼠模型中改善强迫游泳试验的不动时间增加。
  • 在重复社交挫败应激小鼠中,PA-915改善焦虑样、抑郁样行为及认知功能障碍。
  • 单次PA-915在蔗糖偏好试验中产生持续8周的抗抑郁样效应,与氯胺酮相似。

核心结论

  • PA-915在慢性应激诱导的焦虑抑郁小鼠模型中改善焦虑样行为和认知障碍,并发挥快速且持久的抗抑郁效应,为应激相关障碍提出有前景的治疗选择。

研究设计与样本

  • 研究使用重复社交挫败应激、重复给予皮质酮和社会隔离饲养三种慢性应激诱导的小鼠抑郁模型。
  • 在重复社交挫败应激小鼠中采用明暗箱、旷场、高架十字迷宫、蔗糖偏好、强迫游泳、Y迷宫和新物体识别试验进行评估。
  • 研究将PA-915与氯胺酮和氟西汀进行比较,并在非应激对照小鼠中评估行为异常。

主要发现

  • PA-915改善了三种慢性应激小鼠模型中强迫游泳试验的不动时间增加。
  • 在重复社交挫败应激小鼠中,PA-915改善了焦虑样和抑郁样行为及认知功能障碍。
  • 在蔗糖偏好试验中,单次给予PA-915的小鼠抗抑郁样效应持续8周,与氯胺酮观察到的效应相似。
  • 在非应激对照小鼠中,PA-915未诱导过度活动、认知功能障碍或依赖等行为异常。

临床怎么用

  • PA-915作为PAC1拮抗剂,在慢性应激小鼠模型中显示快速且持久的抗抑郁样效应,提示靶向PAC1可能成为应激相关障碍的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stress-related disorders, such as depression and anxiety, have been one of the most important medical issues. Accumulating evidence suggests that the activation of the pituitary adenylate cyclase-activating polypeptide and its receptor PAC1 are involved in the stress axis and the development of stress-related disorders. We recently developed PA-915, a small-molecule, non-peptide, high-affinity PAC1 antagonist, and demonstrated that it significantly suppresses anxiety-like behavior in acute stress-induced mice. In this study, we aimed to investigate the behavioral effects of PA-915 in chronic stress-induced mouse models of depression, which included repeated social defeat stress, repeated corticosterone administration, and social isolation rearing. PA-915 ameliorated the increased immobility time in the forced swim test in these stress-induced mice. In repeated social defeat stress mice, PA-915 improved anxiety-like and depression-like behaviors and cognitive dysfunction, as assessed by the light-dark, open field, elevated plus maze, sucrose preference, forced swim, Y-maze, and novel object recognition tests. In addition, we evaluated the usefulness of PA-915 as an antidepressant and compared it with ketamine and fluoxetine. In the sucrose preference test, an antidepressant-like effect was observed for 8 weeks in mice that received a single dose of PA-915, which was a similar effect observed with ketamine. In non-stressed control mice, PA-915 did not induce behavioral abnormalities, such as hyperlocomotion, cognitive dysfunction, or dependency. The present results show that PA-915 improves anxiety-like behaviors and cognitive impairment and exerts rapid and long-lasting antidepressant effects in chronic stress-induced mouse models of anxiety and depression, proposing a promising treatment option for stress-related disorders.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Shintani Y, Hayata-Takano A, Takasaki I, et al. Rapid and long-lasting antidepressant-like effects of the pituitary adenylate cyclase-activating polypeptide receptor antagonist PA-915 in chronic stress mouse models. Mol Psychiatry. 2025. PMID: 40908362. doi:10.1038/s41380-025-03209-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。